Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

FDA Warns Patients With Myeloma About Pepaxto: Drug Increased Death Rates in Clinical Trial

July 29th 2021, 12:00pm


Patients with myeloma who are receiving Pepaxto should discuss the potential risks and benefits of continued treatment with the drug.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021, 1:00pm


About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

FDA Approves Darzalex Faspro for Second-Line Treatment of Multiple Myeloma

July 12th 2021, 1:52pm


Darzalex Faspro has received FDA approval for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who previously received one line of therapy.

Former Defense Secretary Donald Rumsfeld Dies From Multiple Myeloma

July 1st 2021, 1:30pm


Donald Rumsfeld, who died from multiple myeloma, served as secretary of defense under Presidents Gerald R. Ford and George W. Bush.

Preventative Kineret May Ease CAR T-Cell Therapy Side Effects in Multiple Myeloma

June 24th 2021, 1:00pm


Recent findings merit further study of the immunosuppressive drug as therapy in patients with multiple myeloma.

Adding Darzalex to Standard of Care May Improve Survival in Newly Diagnosed Multiple Myeloma

June 22nd 2021, 9:00pm


Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

Novel Injectable Drug Shows Promise in Relapsed/Refractory Myeloma

June 11th 2021, 1:00pm


Treatment with an investigational drug induced high response rates in patients with relapsed or refractory multiple myeloma.

Single-Injection CAR-T Cell Therapy Improves Long-Term Treatment Responses in Relapsed/Refractory Multiple Myeloma

June 8th 2021, 9:00pm


Patients with relapsed/refractory myeloma who were previously treated with three or more therapies responded to an infusion of a novel CAR-T cell therapy up to 18 months with no new side effects compared with 12-month results of this study.

Kyprolis-Based Regimen Induces Similar Results as Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

June 8th 2021, 6:30pm


The study’s lead author noted that a survival outcome, along with other results, was similar among the two groups.

Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myeloma

June 6th 2021, 8:00pm


After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.